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Abstract: Background:  Despite evidence for the general effectiveness of psychological
therapies, there exists substantial heterogeneity in patient outcomes. We aimed to
identify factors associated with baseline severity of depression and anxiety symptoms,
rate of symptomatic change over the course of therapy, and symptomatic recovery in a
primary mental health care setting.
Methods:  Using data from a service evaluation involving 35,527 patients in England’s
psychological and wellbeing (IAPT) services, we applied latent growth models to
explore which routinely-collected sociodemographic, clinical, and therapeutic variables
were associated with baseline symptom severity and rate of symptomatic change. We
used a multilevel logit model to determine variables associated with symptomatic
recovery.
Results:   Being female, younger, more functionally impaired, and more
socioeconomically disadvantaged was associated with higher baseline severity of both
depression and anxiety symptoms. Being older, less functionally impaired, and having
more severe baseline symptomatology was associated with more rapid improvement of
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
both depression and anxiety symptoms (male gender and greater socioeconomic
disadvantage were further associated with rate of change for depression only).
Therapy intensity and appointment frequency seemed to have no correlation with rate
of symptomatic improvement. Patients with lower baseline symptom severity, less
functional impairment, and older age had a greater likelihood of achieving symptomatic
recovery (as defined by IAPT criteria).
Conclusions:   We must continue to investigate how best to tailor psychotherapeutic
interventions to fit patients’ needs. Patients who begin therapy with more severe
depression and/or anxiety symptoms and poorer functioning merit special attention, as
these characteristics may negatively impact on recovery.
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Evidence abounds for the effectiveness of psychological therapies in treating a wide 52 
range of mental health problems (Barth et al., 2013; Cristea et al., 2017; Cuijpers, 53 
Cristea, Karyotaki, Reijnders, & Huibers, 2016; Pim Cuijpers et al., 2014; Lambert, 54 
2013). However, it is widely acknowledged that treatment outcomes vary greatly 55 
between individuals with a significant proportion not responding at all (Van, Dekker, 56 
Peen, Van Aalst, & Schoevers, 2008; Van, Schoevers, et al., 2008). The ability to 57 
explain why individuals respond differently to therapy provides important supplementary 58 
information to advance our understanding of ‘what works for whom’ (Stuart A. Green et 59 
al., 2015; Van, Dekker, et al., 2008). Characterising the basis of heterogeneity in 60 
baseline symptom severity, rates of symptomatic change during therapy, and treatment 61 
outcomes enables us to identify variables related to treatment success and thus may 62 
constitute a step toward more personalised care. Furthermore, provision of appropriate, 63 
tailored treatment enables efficient allocation of limited mental health resources.  64 
Much effort has gone into understanding the reasons for variation in therapy 65 
response. At the patient level alone, more than 200 factors have been proposed to 66 
potentially influence therapy outcomes (Norcross & Wampold, 2011). These variables 67 
include sociodemographic characteristics (e.g. age (Amati, Banks, Greenfield, & Green, 68 
2018; Marttunen, Välikoski, Lindfors, Laaksonen, & Knekt, 2008; Robinson, Kellett, & 69 
Delgadillo, 2020; Wolitzky-Taylor, Arch, Rosenfield, & Craske, 2012), gender (Amati et 70 
al., 2018; P. Cuijpers et al., 2014; Wolitzky-Taylor et al., 2012), socioeconomic status 71 
(Amati et al., 2018; S. A. Green et al., 2015; Marttunen et al., 2008), and ethnicity 72 
(Amati et al., 2018; Stuart A. Green et al., 2015; Robinson et al., 2020; Saxon, Firth, & 73 




Barkham, 2017; Wolitzky-Taylor et al., 2012)), mental health-related clinical variables 74 
(e.g. pre-treatment disorder severity (Amati et al., 2018; Stuart A. Green et al., 2015; A. 75 
Gyani, R. Shafran, R. Layard, & D. M. Clark, 2013; Marttunen et al., 2008; Robinson et 76 
al., 2020; Saxon et al., 2017; Van, Dekker, et al., 2008; Wolitzky-Taylor et al., 2012), 77 
comorbidities (Amati et al., 2018; Goddard, Wingrove, & Moran, 2015; Marttunen et al., 78 
2008; Wolitzky-Taylor et al., 2012), and psychiatric history (Marttunen et al., 2008)), 79 
social functioning and support (Amati et al., 2018; Lindfors, Ojanen, Jääskeläinen, & 80 
Knekt, 2014; Wang, Mann, Lloyd-Evans, Ma, & Johnson, 2018), and personality traits 81 
(Bucher, Suzuki, & Samuel, 2019; Maarit A. Laaksonen, Knekt, & Lindfors, 2013; M. A. 82 
Laaksonen, Knekt, Sares-Jäske, & Lindfors, 2013). Outcomes further vary by treatment 83 
variables (e.g. therapy modality (Amati et al., 2018; Alex Gyani, Roz Shafran, Richard 84 
Layard, & David M. Clark, 2013; Marttunen et al., 2008), number of sessions attended 85 
(Amati et al., 2018; Alex Gyani et al., 2013; Norcross & Wampold, 2011) and missed 86 
(Amati et al., 2018; Stuart A. Green et al., 2015; Van, Dekker, et al., 2008), time waited 87 
to start treatment (Clark et al., 2018), therapy setting (Amati et al., 2018),  frequency of 88 
sessions (Tiemens et al., 2019), therapeutic alliance (Del Re, Flückiger, Horvath, 89 
Symonds, & Wampold, 2012; Horvath, Del Re, Flückiger, & Symonds, 2011), treatment 90 
engagement (Dixon, Holoshitz, & Nossel, 2016), and patient expectations of therapy 91 
outcome (Porter & Chambless, 2015)) as well as on therapist characteristics and 92 
experience (Amati et al., 2018; Alex Gyani et al., 2013; Nissen-Lie, Monsen, Ulleberg, & 93 
Rønnestad, 2013). Whilst some of these factors influence treatment outcome in a 94 
consistent direction (good therapeutic alliance, for example, consistently leads to more 95 




positive outcomes (Del Re et al., 2012; Horvath et al., 2011)), several show inconclusive 96 
evidence regarding direction of effect (Amati et al., 2018).  97 
Individuals may further vary in their progression through therapy, leading to 98 
heterogeneity in treatment response trajectories (Stuart A. Green et al., 2015). These 99 
trajectories are informative for understanding progress as well as predicting outcomes 100 
(Comninos & Grenyer, 2007; W. Lutz et al., 2014; W. Lutz, Stulz, & Kock, 2009; Stulz, 101 
Lutz, Leach, Lucock, & Barkham, 2007). Research has aimed to characterise 102 
differences in treatment response trajectories, largely through class-based approaches 103 
that classify sub-groups of patients with homogeneous treatment response trajectories 104 
and determine predictors of group membership. These studies have identified varying 105 
number of such sub-groups for a wide range of disorders, including depression 106 
(Cuijpers, Van Lier, Van Straten, & Donker, 2005; Gunn et al., 2013; W. Lutz et al., 107 
2009; Sunderland, Wong, Hilvert-Bruce, & Andrews, 2012),  anxiety (Sunderland et al., 108 
2012), panic disorder (W. Lutz et al., 2014), post-traumatic stress disorder (PTSD) 109 
(Elliott, Biddle, Hawthorne, Forbes, & Creamer, 2005; Stein, Dickstein, Schuster, Litz, & 110 
Resick, 2012), and first-episode psychosis (Hodgekins et al., 2015) . 111 
Previous studies of both therapy outcomes and treatment response trajectories in 112 
psychological therapy have some limitations. First, with few exceptions (Ali et al., 2014; 113 
Flückiger, Grosse Holtforth, Znoj, Caspar, & Wampold, 2013; Green, Barkham, Kellett, 114 
& Saxon, 2014; Wolfgang Lutz, Martinovich, Lyons, Leon, & Stiles, 2007; Saxon et al., 115 
2017), they have not accounted for the structure of longitudinal data in which patients 116 
are nested under individual therapists. Failure to take into account this hierarchical data 117 
structure can result in biased statistical inferences (Stochl et al., 2014). Second, many 118 




of the previous studies have relied upon specialised, non-routine variables (e.g. 119 
measures of therapeutic alliance). Whilst these provide valuable insights, there is a 120 
practical need for easily identifiable, routinely-collected variables, including patients’ 121 
sociodemographic characteristics and clinical features (Van, Dekker, et al., 2008).  122 
These limitations highlight a need for robust studies that use appropriately 123 
complex multilevel models to cope with hierarchical and longitudinal dependencies, as 124 
well as convenient (i.e. readily available in IAPT’s routinely-collected variables) and 125 
practical (i.e. relevant to outcomes of interest) variables to explain heterogeneity in 126 
treatment response trajectories and symptomatic recovery. In this exploratory analysis, 127 
we aimed to identify variables that are associated with (1) baseline symptom severity, 128 
(2) rate of symptomatic change, and (3) symptomatic recovery of patients receiving 129 
psychological therapy in England’s Improving Access to Psychological Therapies (IAPT) 130 




The IAPT programme in England began in 2008 with a direct objective to increase 135 
public access to National Institute for Health and Care Excellence (NICE) approved 136 
psychological therapies for depression and anxiety. IAPT currently assesses over 137 
1,300,000 people annually and delivers therapy to approximately 550,000. The 138 
programme offers low- (step 2) and high-intensity (step 3) treatment. Low-intensity 139 
approaches include guided self-help, psychoeducation, computerised CBT, behavioural 140 
activation, and structured group activity programmes (Clark, 2018). In high-intensity 141 




services, face-to-face cognitive–behavioural therapy (CBT) is the predominant 142 
approach, although there is a wider range of recommended treatments (e.g. eye 143 
movement desensitisation and reprocessing (EMDR), interpersonal psychotherapy 144 
(IPT), counselling for depression, compassion-focused therapy (CFT), and integrative 145 
counselling). On average, patients receive 7 sessions over a period of 3-4 months.  146 
At each session, therapists assess depression and anxiety symptoms using the 147 
9-item Patient Health Questionnaire (PHQ-9) (Kroenke, Spitzer, & Williams, 2001) and 148 
the 7-item Generalized Anxiety Disorder assessment (GAD-7) (Spitzer, Kroenke, 149 
Williams, & Lowe, 2006), respectively. IAPT services adopted these scales nationally 150 
because of their good psychometric properties (Cameron, Crawford, Lawton, & Reid, 151 
2008; Titov et al., 2011) and brevity, and they use them to monitor improvement and 152 
recovery rates. Total scores are computed as sum scores of items (response 153 
categories: 0=Not at all; 1=Several days, 2=More than half the days; 3=Nearly every 154 
day). PHQ-9 scores range from 0 (no depression) to 27 (severe depression), whilst 155 
GAD-7 scores range between 0 (no anxiety) and 21 (severe anxiety). In IAPT, 156 
individuals are described at ‘caseness’, if they score above the clinical cut-off for 157 
depression (PHQ-9 ≥ 10) (Manea, Gilbody, & McMillan, 2012) and/or anxiety (GAD-7 ≥ 158 
8).  159 
 160 
Participants 161 
The primary sample consisted of 35,527 individuals across Cambridgeshire and 162 
Peterborough NHS Foundation Trust and Sussex Partnership NHS Foundation Trust 163 
who accessed IAPT services between February 2018 and December 2018. We 164 




excluded 6,717 individuals deemed not suitable for the service after initial assessment 165 
and those with no longitudinal data (i.e. who only attended one appointment). The 166 
sample analysed for determinants of baseline symptom severity and rate of 167 
symptomatic change consisted of 28,810 individuals (Table 1). 168 
To assess which variables were associated with symptomatic recovery, we 169 
analysed therapy outcomes for a subsample 8,114 individuals comprising those patients 170 
who: a) had non-missing values for both PHQ-9 and GAD-7 scores at first and last 171 
assessment (n=27,835); b) were considered at ‘caseness’ at initial assessment (i.e. 172 
PHQ-9 and/or GAD-7 score was above clinical cut-off, n=20,959); c) had completed 173 
treatment (in any number of sessions, n=10,3081); and d) had non-missing values on all 174 
variables hypothesised to be associated with outcomes (n=8,114). Over 67% (5,438) 175 
individuals achieved symptomatic recovery.  176 
 177 
Outcomes  178 
Our outcomes of interest were baseline symptom severity, rate of symptomatic change, 179 
and symptomatic recovery. We inferred each patient’s baseline symptom severity and 180 
rate of symptomatic change from his/her growth curve (hereafter denoted as treatment 181 
response trajectory), which is estimated using his/her total scores on the corresponding 182 
scale across therapy appointments. Symptomatic recovery in IAPT is achieved when a 183 
patient who is at ‘caseness’ at pre-treatment has dropped below the clinical cut-off for 184 
                                                        
1 In response to a suggestion following peer review, we have also analyzed the sample that included 
individuals who had not completed treatment and whose symptomatic recovery was derived from the last 
recorded session. The results are presented in Appendix 4. 




both depression and anxiety post-treatment (i.e. PHQ-9 < 10 and GAD-7 < 8) (National 185 
Collaborating Centre for Mental Health, 2018). 186 
 187 
Variables tested for association with outcomes 188 
The set of variables tested for associations with our outcomes of interest included three 189 
sociodemographic variables (gender, age, and socioeconomic status), two clinical 190 
variables (baseline symptom severity and baseline level of functioning), and three 191 
therapeutic variables (therapy intensity (low- (step2) or high-intensity (step3)), therapy 192 
frequency (median number of days between sessions), and the number of patients 193 
treated by an individual therapist (caseload)). All of these variables were directly 194 
obtained or derived from data routinely collected in IAPT services (see Supplementary 195 
Table 1 for detailed variable list). 196 
Baseline level of functioning was measured using the 5-item self-report Work and 197 
Social Adjustment Scale (WSAS) (Mundt, Marks, Shear, & Greist, 2002), which 198 
measures personal, occupational, and social functional impairment. Each item on the 199 
WSAS is scored from 0 (no impairment) to 8 (severe impairment), hence total scores 200 
range from 0 to 40, with higher total scores indicating more severe impairment.  201 
Socioeconomic status was estimated using the Index of Multiple Deprivation 202 
(IMD). IMD deciles are publicly available data for postcodes across the UK. Anonymised 203 
data provided by IAPT, however, included only the outward area postcode. The IMD for 204 
each individual was therefore estimated as a median IMD decile for the corresponding 205 
outward area, with lower values representing higher deprivation. 206 





Statistical analysis 208 
We used growth models to estimate patients’ treatment response trajectories of 209 
depression and anxiety symptoms. This modelling approach fits, for each patient, a non-210 
linear trend for the total scores of PHQ-9 or GAD-7 over the course of therapy. We 211 
inferred values for baseline symptom severity and rate of symptomatic change from the 212 
intercept and slope of patients’ treatment response trajectories, respectively. In all 213 
analyses we used Full Information Maximum Likelihood estimator to account for data 214 
missingness. 215 
The IAPT treatment model is based on 12-20 sessions as set out in the NICE 216 
guidelines. Very few individuals attended more than 20 appointments and thus we only 217 
used the first 20 appointments for each patient. We first estimated the basic nonlinear 218 
growth model (with intercept, slope, and quadratic term as latent variables) anchored at 219 
every attended appointment (see Supplementary Figure 1).   220 
At this stage, we investigated whether the individual treatment trajectories cluster 221 
into homogeneous classes using a growth mixture model. If few interpretable classes 222 
are found, then the variables associated with baseline symptom severity and rate of 223 
symptomatic change could be considered for these classes instead of individual 224 
trajectories. However, we did not find such classes (see Appendix 1) and thus carried 225 
out the analysis on an individual level.  226 
Next, we reparameterised the model so that the slope represented change over 227 
the first 7 appointments rather than between the first and the second appointments as in 228 
the basic model (note that all 20 appointments are still used to estimate this model). We 229 




chose to report the symptomatic change in the first 7 appointments because it is the 230 
average number of appointments nationally and thus represents a typical length of 231 
therapeutic intervention within IAPT (Public Health England, 2019). We detail the model 232 
in Appendix 2.  233 
Additional analytical complexity stemmed from the multilevel structure of the data 234 
(multiple patients received therapy from the same therapist). Accounting for this 235 
analytically provides unbiased treatment response trajectories. In addition, it allowed us 236 
to assess variables associated with the average rate of symptomatic change for each 237 
therapist’s patients. Additional details are provided in Appendix 3. 238 
We then added variables considered to be related with the intercepts (baseline 239 
symptom severity) and slopes (rate of symptomatic change) of treatment response 240 
trajectories to the reparameterised model. At the patient level (the within-level part of 241 
the model), we included gender, age, socioeconomic status, and baseline level of 242 
functioning (WSAS). We included therapy intensity (low vs high) as an important 243 
covariate accounting for different therapeutic approaches applied for low and high 244 
intensity IAPT patients. Therapy frequency was considered only in the context of the 245 
slope as its association with the intercept would be conceptually non-sensical). We also 246 
explored the association between baseline symptom severity and rate of symptomatic 247 
change. At the therapist level (the between-level part of model), we examined whether 248 
caseload was associated with a) the average rate of symptomatic change and b) 249 
recovery for each therapist’s patients.  250 
We used a multilevel logit model for variables associated with the binary clinical 251 
endpoint of symptomatic recovery. The set of variables examined in relation to 252 




symptomatic recovery was identical to those of rate of symptomatic change except that 253 
a) we included baseline symptom severity of both depression and anxiety (as recovery 254 
in IAPT requires having scores below corresponding threshold on both measures) and 255 
b) these baseline symptom severities were operationalised as total scores of PHQ-9 256 
and GAD-7 at initial assessment (i.e. not as intercepts of treatment response 257 
trajectories). Total PHQ-9 and GAD-7 scores at baseline were moderately correlated 258 
(r=0.46), allowing inclusion of both variables in the same model. We bootstrapped the 259 
model (1000 iterations) to obtain bootstrapped confidence intervals for odds ratios. We 260 
conducted all analyses in MPlus 8.4 (Muthén & Muthén, 1998-2019) and R 3.6.3 (R 261 
Core Team, 2019). 262 




Sample and variable descriptives 267 
Table 1 provides the sociodemographic characteristics and basic descriptive statistics of 268 
variables hypothesised to be associated with outcomes. 269 
 270 
--------------------------------- insert Table 1 about here --------------------------------------- 271 
 272 
 273 




Growth models  274 
The basic nonlinear growth models fit the data well (PHQ-9: RMSEA=0.034, CFI=0.952, 275 
TLI=0.955, SRMR=0.082; GAD-7: RMSEA=0.032, CFI=0.951, TLI=0.954, 276 
SRMR=0.080). Figure 1 depicts the estimated mean trajectories for the two scales. The 277 
modelled mean baseline symptom severity (intercept) had a value of 13.5 for the PHQ-9 278 
and 12.6 for the GAD-7. The mean slopes (-0.9 for the PHQ-9 and -0.8 for the GAD-7) 279 
reflect the average change in scores between the first and second therapy session. 280 
Such interpretation is not very informative in regard to understanding improvement over 281 
the course of the therapy. In the reparameterised growth model, the slopes represent 282 
change over the first 7 sessions. Results suggest that the average improvement across 283 
7 therapy sessions is 4.2 points on the PHQ-9 and 4.0 points on the GAD-7 (see 284 
Appendix 2 for details).  285 
 286 
--------------------------------- insert Figure 1 about here --------------------------------------- 287 
 288 
 289 
Variables associated with baseline symptom severity and rate of symptomatic 290 
change  291 
Tables 2 and 3 include estimated regression coefficients (including standardised 292 
estimates) for depression and anxiety symptoms, respectively.  293 
 294 




Variables associated with baseline symptom severity and rate of symptomatic change 295 
for depression (PHQ-9)  296 
Patients’ modelled baseline symptom severity (the within-level intercept of his/her 297 
treatment response trajectory) was significantly related to gender (females have greater 298 
baseline symptom severity), age (younger patients have greater baseline symptom 299 
severity), baseline functioning (patients with more functional impairment have greater 300 
baseline symptom severity), socioeconomic status (patients living in areas of higher 301 
deprivation have greater baseline symptom severity), and therapy intensity. The 302 
significant positive relationship between baseline symptom severity and therapy 303 
intensity confirms that patients with more severe depression symptoms tend to be 304 
assigned to high-intensity therapy. In terms of standardised coefficients, baseline 305 
symptom severity had the strongest relationship with baseline functioning scores. 306 
Patients’ rate of symptomatic change for depression (the within-level slope of 307 
patients’ treatment response trajectories) was most strongly related (in terms of 308 
magnitude of impact) to their baseline depression severity. More specifically, the higher 309 
the baseline symptom severity, the faster the improvement. Additionally, the rate of 310 
symptomatic change was related to gender (males improve more rapidly), age (older 311 
patients improve more rapidly), baseline level of functioning (patients with less 312 
functional impairment improve more rapidly), and socioeconomic status (patients living 313 
in areas of higher deprivation improve more rapidly). The improvement rate was not 314 
significantly related to therapy frequency or intensity. 315 




The average improvement of a particular therapist’s patients (the between-level 316 
part of the model), was significantly related to that therapist’s caseload, however, in an 317 
unexpected direction – a larger caseload was related to more rapid improvement. 318 
 319 
--------------------------------- insert Table 2 about here --------------------------------------- 320 
 321 
 322 
Variables associated with baseline symptom severity and rate of symptomatic change 323 
for anxiety (GAD-7) 324 
Results for the GAD-7 treatment response trajectories were similar to those of the PHQ-325 
9. However, contrary to the PHQ-9 results, the relationship between baseline symptom 326 
severity and therapy intensity was at the borderline of statistical significance and was in 327 
the opposite direction than for depression. Furthermore, gender and socioeconomic 328 
status were not related to the rate of improvement for GAD-7 scores. Finally, 329 
considering the standardised coefficients, functioning has a larger effect size for anxiety 330 
than for depression (with lower impairment related to more rapid improvement), when 331 
controlling for all other variables.  332 
 333 
--------------------------------- insert Table 3 about here --------------------------------------- 334 
 335 
 336 
Variables associated with symptomatic recovery 337 




Table 4 shows results of a multilevel logit model with symptomatic recovery as the 338 
outcome. Baseline symptom severity, age, and baseline level of functioning were 339 
significantly related to symptomatic recovery, even when bootstrap was applied. 340 
Specifically, with each additional point on the PHQ-9 or GAD-7 at the beginning of 341 
therapy, the chances of symptomatic recovery decreases by approximately 5.8% and 342 
6.3%, respectively. Similarly, an increase of one point on the WSAS is associated with 343 
an approximate 2.4% reduction in chances of recovery. Each additional year of age 344 
increases odds of recovery by approximately 0.8%.   345 
Therapy intensity and frequency were significantly related to symptomatic 346 
recovery, however, bootstrapped odd ratios were not and thus the results should be 347 
interpreted with caution. In addition, both variables have a relatively small effect on 348 
recovery. For example, an increase of a day in the median number of days between 349 
sessions reduced the probability of recovery by 0.7% and being assigned to high-350 
intensity therapy lowers chances of recovery by approximately 11.2% when adjusting 351 
for all other variables (it is important to note, however, that high-intensity therapists 352 
generally see more complex and severe patients). 353 
Socioeconomic status, gender, and therapist caseload were not significantly 354 
associated with symptomatic recovery.  355 
The results for the sample including those individuals who had not yet completed 356 
therapy or who had dropped out but whose symptomatic recovery was derived from the 357 
last recorded session, are presented in Appendix 4. They were very similar to those 358 
presented in Table 4. 359 
  360 




--------------------------------- insert Table 4 about here --------------------------------------- 361 
 362 
Discussion 363 
In this study, we explored which sociodemographic, clinical, and therapeutic variables 364 
may be related to (1) baseline symptom severity, (2) rate of symptomatic change, and 365 
(3) symptomatic recovery (as defined by IAPT criteria) for patients with depression and 366 
anxiety engaging in psychological therapy in IAPT services. Importantly, our predictors 367 
were all variables routinely collected in IAPT services and included gender, age, and 368 
socioeconomic status, clinical variables (baseline depression and anxiety scores, and 369 
baseline level of functioning), and therapeutic variables (therapy intensity and median 370 
number of days between sessions (i.e. frequency)). Our multilevel approach also 371 
allowed us to test the relationship between therapists’ IAPT caseload and the average 372 
rate of symptomatic change and recovery of their corresponding patients.  373 
Treatment response trajectories 374 
Whilst baseline severity of both depression and anxiety symptoms was significantly 375 
related to all included variables (i.e. gender, age, baseline functioning, socioeconomic 376 
status, and therapy intensity), baseline functioning had by far the largest effect sizes 377 
(whereby greater functional impairment was associated with more severe 378 
symptomatology). Age, baseline functioning, baseline symptom severity, and therapist 379 
caseload were significantly related to the rate of change for both depression and anxiety 380 
symptoms, and gender and socioeconomic status were additionally related to rate of 381 
change for depression (but not anxiety) symptoms. Therapy characteristics such as 382 
intensity and frequency seemed to have no relation to the rate of symptomatic change. 383 




Baseline symptom severity was the most important variable associated with rate of 384 
change for both depression and anxiety symptoms, whereby patients with more severe 385 
symptomatology at the start of therapy improved more rapidly. On average, a 1-point 386 
difference in total score on the corresponding scale between two patients at baseline 387 
results in an expected difference of 0.748 (i.e. 1 – 0.252) points on the PHQ-9 and 388 
0.738 (i.e. 1 – 0.262) points on the GAD-7 between them at 7th session. Baseline 389 
functioning was the only other variable to show a clinically relevant effect size at the 390 
individual level (whereby greater functional impairment at the start of therapy was 391 
related to slower improvement), but only for anxiety symptoms.  392 
Our finding that greater baseline severity of depression and anxiety symptoms 393 
was associated with more rapid symptom improvement is unusual. In general, others 394 
have found either that baseline severity negatively impacts the rate of symptomatic 395 
improvement (e.g. Sunderland and colleagues’ (2012) study of online CBT for 396 
depression and anxiety disorders) or has no relationship (e.g. Comninos and Greyner’s  397 
(2007) study of early rapid response in supportive-expressive dynamic psychotherapy 398 
for major depression). The importance of baseline symptom severity extends beyond 399 
symptomatic change, as Hodgekins et al. (2015) demonstrate in their finding that 400 
baseline severity of psychotic symptoms serves as a predictor of belonging to a ‘poorer’ 401 
trajectory of social recovery for patients with first episode psychosis.  402 
We located only one study that reflected our finding that baseline severity was 403 
positively related to the rate of symptomatic improvement (Elliott and colleagues’ (2005) 404 
study of veterans receiving treatment for PTSD). It is conceivable that help-seeking 405 
individuals with higher baseline symptom severity may be more motivated to engage 406 




with therapy in an effort to overcome more severe symptoms (‘the gift of desperation’) 407 
and that increased engagement positively impacts on treatment outcomes (Dixon et al., 408 
2016). However, this explanation is perhaps more reasonable for anxiety symptoms 409 
than depression symptoms, wherein greater severity may instead be a barrier to 410 
engagement. Furthermore, it is important to consider the potential for statistical artefacts 411 
when interpreting these effect sizes, as patients starting with more severe symptoms 412 
have greater scope for improvement.  413 
Our finding about the negative impact of functional impairment on rate of 414 
symptomatic improvement is more consistent with the literature. For example, Lutz and 415 
colleagues’ (2014) study of CBT for patients with panic disorder highlighted the 416 
importance of social functioning in predicting class membership (as characterised in 417 
part by rate of symptomatic change). Poor functioning is a well-documented barrier to 418 
symptomatic improvement. Many people with greater functional impairment are 419 
unemployed and/or have fewer social contacts, and thus are missing two key protective 420 
factors associated with positive mental health. Poor functioning is further related to 421 
barriers in engaging with therapy. For example, poorer functioning may equate to fewer 422 
resources for use in therapy or poor attendance (due to various reasons including 423 
financial or social difficulties and anxiety). Thus, interventions for those with poorer 424 
social functioning may require additional considerations, such as strategies for returning 425 
to work or building up social networks and overcoming barriers related to each of these 426 
goals (Knight et al., 2019). 427 
At the therapist level, our finding that a larger therapist caseload was associated 428 
with more rapid improvement could indicate that more frequent application of IAPT 429 




techniques facilitates greater therapist competency. Alternatively, this could simply 430 
indicate that more competent therapists are assigned more patients. In either case, this 431 
result should not be interpreted causally. First, the caseload variable represents only the 432 
number of IAPT patients seen by each therapist and is not weighted for the number of 433 
days worked in IAPT. It is possible that each therapist sees additional patients outside 434 
of IAPT, in which case the effect of total caseload would be unmeasured in our 435 
analyses. Second, some IAPT therapists focus on specific groups of patients (e.g. 436 
patients with long-term physical conditions), which could affect their caseload and 437 
potentially bias results; however, this specialisation applies to a relatively small group of 438 
therapists. 439 
 440 
Symptomatic recovery 441 
Higher chance of symptomatic recovery, as defined by IAPT criteria, was associated 442 
with lower baseline severity of depression and anxiety symptoms, lower functional 443 
impairment, and increased age, with baseline symptom severity having the greatest 444 
effect. These findings are not particularly surprising: whilst starting therapy with a higher 445 
score on the PHQ-9/GAD-7 enables more scope for improvement (hence the sensibility 446 
of its association with faster symptomatic improvement), it also implies a further 447 
distance to IAPT’s recovery ‘threshold’. Several other studies have found similar results 448 
in terms of baseline symptom severity (Amati et al., 2018; Marttunen et al., 2008), 449 
including two within the IAPT setting (S. A. Green et al., 2015; A. Gyani et al., 2013). It 450 
is conceivable that patients starting therapy with greater symptom severity and 451 
functional impairment have more difficulty engaging in treatment than those with less 452 




severe symptomatology and impairment. These patients may also be at increased risk 453 
for additional psychiatric comorbidities, including psychotic experiences (Stochl et al., 454 
2015), which could further contribute to the reduced chance of recovery (Knight et al., 455 
2019).  456 
In interpreting our results, it must be acknowledged that people with ‘less 457 
favourable’ characteristics (e.g. those with higher baseline symptom severity/functional 458 
impairment) do not necessarily benefit less from therapy. It is important to remember 459 
that the definition of symptomatic recovery (as routinely used in IAPT for performance 460 
monitoring purposes) is centred around absolute improvement (i.e. whether their 461 
symptoms were reduced beyond the recovery ‘threshold’) rather than relative 462 
improvement (i.e. the difference between baseline and final symptom severity). Hence, 463 
in order to be most informative, results about symptomatic recovery should be 464 
contextualised within our discussion of treatment response trajectory. 465 
 466 
Strengths and limitations 467 
The main strength of this study is the large clinical sample. Furthermore, although this is 468 
not the first study that has explored variables related to symptomatic improvement and 469 
recovery in the context of psychological therapy, we used an analytical approach that is 470 
more appropriate for the complex data structure of longitudinal outcomes nested under 471 
therapists. A further strength is the applicability to clinical settings in general, and to the 472 
IAPT setting in particular, as we used routinely-collected, easily obtained measures in 473 
our analyses. However, this may also be considered as a weakness, as many 474 
potentially relevant variables were not available for inclusion in our analyses, including 475 




medication use, treatment history, therapist competence, and therapeutic alliance, as 476 
well as other key risk and protective factors. The absence of such prognostic variables 477 
can be seen in the relatively low R2 values for our models. 478 
 We acknowledge additional limitations in terms of sample selection and available 479 
variables. The selection of referrals meeting IAPT service criteria for treatment may 480 
have introduced Berkson’s bias into our analyses, particularly in those regarding 481 
recovery. We were unable to quantify this bias because we have no recovery data for 482 
referrals not admitted to IAPT. Furthermore, the subsample of 8,114 with the requisite 483 
data for evaluation of predictors of recovery may not be representative of the full sample 484 
as patients drop out for non-random reasons; again, this is inherent in many clinical 485 
samples where drop outs may be due to recovery or worsening. Therefore, inferences 486 
from these findings need to be made with caution. Finally, whilst our sample size was 487 
large, it represented only two mental health trusts, which may limit the generalisability of 488 
our results.    489 
In terms of limitations relating to individual variables,, we could not investigate 490 
relationship between ethnicity and treatment response trajectories as we had very few 491 
Black, Asian, and Minority Ethnic (BAME) individuals in our sample (though this broadly 492 
reflects the proportion of BAME people accessing IAPT nationally). Whilst beyond the 493 
scope of this paper, the low proportion of BAME individuals accessing IAPT services 494 
merits careful consideration. Low participation may be due to a number of causes, 495 
including individual factors (e.g. personal attitudes toward services), service-level 496 
factors (e.g. inaccessibility or unacceptability), and wider cultural issues (e.g. 497 
discrimination and stigma). Furthermore, our calculation of socioeconomic status has 498 




limitations; as IAPT does not collect this information on an individual level, we derived 499 
this variable by using the outward code of each individual’s postcode to collect the 500 
median IMD decile for the area. Finally, in terms of caseload, we were only able to 501 
identify the number of patients the therapist sees within the IAPT setting. Yet, it is not 502 
uncommon for IAPT therapists to see additional patients outside of IAPT. 503 
     504 
 505 
Conclusions 506 
Therapist confidence and self-efficacy are important factors for determining 507 
therapy effectiveness (Green, Barkham, Kellett, & Saxon, 2014; Heinonen, Lindfors, 508 
Laaksonen, & Knekt, 2012). Equally as important, patients’ positive expectations of 509 
therapy outcome have been consistently linked to better actual outcomes (Mondloch, 510 
Cole, & Frank, 2001). Whilst therapists and patients may worry about progress and 511 
outcomes in the context of more severe baseline symptomatology, our findings suggest 512 
that they can take courage in the knowledge that more ‘unwell’ patients actually have 513 
the potential to improve more rapidly. Moreover, this finding demonstrates the gains 514 
possible for patients with more severe depression and anxiety in services offering short-515 
term psychological therapies.  516 
Furthermore, our results about variables associated with symptomatic recovery 517 
are useful for highlighting groups of patients that may benefit from additional or more 518 
intensive intervention. One such group consists of patients who begin therapy with more 519 
severe depression and/or anxiety symptoms and poorer functioning, as these two 520 
characteristics have a significant negative impact on symptomatic recovery. In order to 521 




ensure that everyone has the potential to reach the IAPT symptomatic recovery 522 
threshold, we must continue to investigate how to best tailor interventions to fit 523 
individual patients’ needs. 524 
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Figure 1: Estimated average growth model trajectories for PHQ-9 (blue) and GAD-7 (red). Scale score is computed as sum 
score of all items. 
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Table 1: Sample characteristics and descriptive statistics for variables 
hypothesised to be associated with outcomes 














41.3 (15.3) 39.4 (13.3) 
Functioning (WSAS): 
mean (sd) 















therapies in days): 
median (IQR) 
14.0 (12.5) 14.0 (10) 
Baseline symptom severity PHQ-9: 
mean (sd) 
13.6 (6.3) 14.7 (5.3) 
Baseline symptom severity GAD-7: 
mean (sd) 
12.6 (5.3) 14.0 (4.1) 
Number of patients 
per therapist: 
mean (sd) 

































* Of those initially assigned to low or high intensity therapy 9,544 individuals (33.1%) were stepped up 
or down in intensity during the therapy course. 
OCD=Obsessive-compulsive disorder; PTSD=Post-traumatic stress disorder 
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Table 2: Regression coefficients for conditional multilevel growth model of 
depressive symptoms 










BSS Gendera  -0.401 (0.081) -0.034 (0.007) <0.001 
BSS Age -0.021 (0.003) -0.051 (0.007) <0.001 




-0.177 (0.026) -0.061 (0.009) <0.001 
BSS Therapy intensity 0.374 (0.103) 0.032 (0.009) <0.001 
RoSCh Gendera -0.190 (0.073) -0.025 (0.010) 0.009 
RoSCh Age -0.017 (0.003) -0.063 (0.011) <0.001 
RoSCh Functioning (WSAS) 0.022 (0.005) 0.055 (0.013) <0.001 
RoSCh 
Socioeconomic status 
(median IMD)  
0.068 (0.032) 0.037 (0.017) 0.037 
RoSCh Therapy intensity -0.005 (0.090) -0.001 (0.012) 0.960 
RoSCh Therapy frequency 0.002 (0.006) 0.010 (0.026) 0.681 
RoSCh 
Baseline symptom severity 
(Intercepts within) 




RoSCh Number of patients -0.005 (0.003) -0.319 (0.153) 0.037 
* All independent variables are cross-adjusted 
a Reference group=females 
RoSCh = Rate of symptomatic change (where more negative slopes indicate more 
rapid improvement), BSS=Baseline Symptom Severity 
R-squares: RoSCh=0.138, BSS=0.321 
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Table 3: Regression coefficients for conditional multilevel growth model of 
anxiety symptoms 










BSS Gendera -0.937 (0.072) -0.095 (0.007) <0.001 
BSS Age -0.036 (0.003) -0.102 (0.008) <0.001 




-0.115 (0.024) -0.048 (0.010) <0.001 
BSS Therapy intensity -0.193 (0.097) -0.020 (0.010) 0.048 
RoSCh Gendera -0.092 (0.063) -0.014 (0.010) 0.145 
RoSCh Age -0.014 (0.003) -0.058 (0.010) <0.001 




0.013 (0.024) 0.008 (0.015) 0.577 
RoSCh Therapy intensity 0.005 (0.088) 0.001 (0.013) 0.955 
RoSCh Therapy frequency 0.008 (0.005) 0.042 (0.025) 0.091 
RoSCh 
Baseline symptom severity 
(Intercepts within) 




RoSCh Number of patients -0.006 (0.002) -0.322 (0.092) 0.001 
* All independent variables are cross-adjusted 
a Reference group=females 
RoSCh = Rate of symptomatic change (where more negative slopes indicate more 
rapid improvement), BSS=Baseline Symptom Severity 
R-squares: RoSCh=0.127, BSS=0.188 
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Table 4: Regression coefficients, odds ratios and bootstrapped odds ratios for 
variables hypothesised to be associated with symptomatic recovery 




















-0.065 (0.007) 0.937 <0.001 
0.935 (0.916-
0.953) 
Gender 0.076 (0.049) 1.079 0.138 
1.090 (0.947-
1.248) 
Age 0.008 (0.002) 1.008 <0.001 
1.008 (1.003-
1.014) 
Functioning (WSAS) -0.024 (0.003) 0.976 <0.001 
0.975 (0.966-
0.985) 
Therapy frequency -0.008 (0.003) 0.992 0.015 
0.994 (0.985-
1.003) 










Number of patients 0.000 (0.001) 1.000 0.446 
1.001 (0.999-
1.002) 
* All independent variables were cross-adjusted 
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Appendix 1: Classes of treatment response trajectories. 
 
A growth mixture model with 1-9 classes was fitted to the data to establish if 
treatment response trajectories cluster into interpretable homogeneous classes. The 
fit of the estimated models is presented in Supplementary Table 1. Dropping indices 
such as Bayesian Information Criterion (BIC), Akaike Information Criterion (AIC) in 
combination with entropy values do not support few homogeneous, yet distinct 
classes. 
 












1-class 27835 23 -555535 1111117 1111306 - 
2-classes 27835 27 -514358 1028771 1028993 0.828 
3-classes 27835 31 -498217 996497 996752 0.801 
4-classes 27835 35 -491410 982890 983178 0.773 
5-classes 27835 39 -488228 976534 976855 0.743 
6-classes 27835 43 -485876 971839 972193 0.723 
7-classes 27835 47 -484107 968307 968694 0.712 
8-classes 27835 51 -482741 965585 966005 0.688 






1-class 27832 23 -531038 1062122 1062311 - 
2-classes 27832 27 -493235 986523 986745 0.816 
3-classes 27832 31 -479348 958757 959012 0.78 
4-classes 27832 35 -473553 947177 947465 0.746 
5-classes 27832 39 -471127 942332 942653 0.719 
6-classes 27832 43 -468636 937358 937713 0.699 
7-classes 27832 47 -467019 934131 934518 0.676 
8-classes 27832 51 -465694 931491 931911 0.669 
9-classes 27832 55 -464716 929543 929995 0.660 
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Appendix 2: Reparameterised model 
The traditional parameterisation of growth models is useful for estimating the shape 
of treatment response trajectories but limits the interpretation of the slope as the 
average improvement in scores between the first and second therapy session when 
the trajectory shape is, as in our case, nonlinear. Fortunately, the model can be 
reparameterised such that the slope can be interpreted as growth between two 
arbitrarily-chosen appointments. Times for the appointments are estimated for all 
except for the anchoring appointments (i.e. the anchor appointments are fixed), so 
that the. Non-linearity of recovery trajectories is still taken into account. In our case, 
we have chosen the 1st and the 7th appointments as our anchoring appointments. 
Therefore, the slope can be interpreted as the difference in modelled scores between 
these two appointments. The result is a linear model, although the non-linearity 
resulting from differential changes in symptoms between appointments is still taken 
into account. The fit of this model is slightly worse compared to  non-reparameterised 
model, yet still acceptable for both the PHQ-9 (RMSEA=0.042, RMSEA 90% 
CI=(0.042-0.043), CFI=0.923, TLI=0.922, SRMR=0.145) and the GAD-7 
(RMSEA=0.042, RMSEA 90% CI=(0.041-0.043), CFI=0.929, TLI=0.922, 
SRMR=0.183). The treatment response trajectories of the reparameterised model are 
depicted in Supplementary Figure 2). The slope of the reparameterised growth model 
has a value of -4.208 for the PHQ-9 and of -4.005 for the GAD-7. This suggests that, 
on average, patients improve by about 4.2 points on PHQ-9 score, and by 4 points 
on GAD-7 score, over the course of 7 appointments. The correlation between slope 
and the intercept was negative (-0.331 for PHQ-9 and -0.311 for GAD-7), suggesting 
that individuals who are initially more depressed and anxious tend to improve faster 
on the corresponding scale. 
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Supplementary Figure 2: Estimated growth model trajectories for the reparameterised growth model (PHQ-9 in blue and GAD-
7 in red) 
 
Appendix 3: Multilevel modelling considerations 
Here we have now investigated the amount of variance accounted for by the 
therapist and site levels in our outcomes of interest (slopes and intercepts of growth 
curves and recovery). For this we used the intraclass correlation coefficient (ICC) and 
design effect (DEFF) coefficient. ICCs > 0.05 (5%) and DEFFs > 2 indicate a need for 
multilevel modelling at the corresponding level (Lai & Kwok, 2015; Muthen & Satorra, 
1995). DEFF is inappropriate for very small or very large cluster sizes (Lai & Kwok, 
2015) and thus we do not report it for sites (where the average cluster size is of 
thousands). Results are presented in the table below and suggest that using a two-
level model is appropriate for this dataset. 
 
Supplementary Table 2: Intraclass correlation coefficients and design effects 
for therapist and site levels. 
Level Outcome Intraclass correlation 
coefficient 





Therapist Slopes (rates of 
symptomatic change) 
0.051 (5.1%) 53.73 3.67 
Intercepts (Baseline 
symptom severity) 
0.090 (9.0%) 53.73 5.76 
Recovery 0.056 (5.6%) 19.60 2.03 
Site Slopes (rates of 
symptomatic change) 
0.003 (0.3%)* 13,916 - 
Intercepts (Baseline 
symptom severity) 
0.005 (0.5%)* 13,916 - 
Recovery -** 4,057 - 
* only 2 clusters (sites) available. Interpret with caution 
** estimation failed – likely as a combination of binary outcome (recovery) and 2 clusters (sites) 
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Appendix 4: Variables associated with symptomatic recovery for the more 
inclusive sample (n=13,349) 
 
This additional analysis presents the results of the recalculation of our recovery 
model for a sample that consists of n=8,114 individuals who completed treatment (as 
presented in the main paper) as well as an additional n=5,235 individuals who a) had 
not yet completed treatment or had dropped out, b) had attended at least 3 therapy 
sessions, and c) had both PHQ-9 and GAD-7 scores available at their last recorded 
session. Their symptomatic recovery status was derived from their PHQ-9 and GAD-
7 scores at the last recorded session such that they had “recovered” if both scores 
were below IAPT recovery thresholds (PHQ-9 < 10 and GAD-7 < 7).  The regression 
coefficients (and odds ratios) are very similar to those presented in the main text (see 
Table 4). Standard errors and p-values were generally smaller in this more inclusive 
sample because of the larger sample size.  
 
Supplementary Table 3: Regression coefficients, odds ratios and bootstrapped 
odds ratios for variables hypothesised to be associated with symptomatic 
recovery for the more inclusive sample (n=13,349) 













-0.074 (0.005) 0.929 <0.001 0.939 (0.920-0.958) 
Baseline symptom 
severity GAD-7 
-0.062 (0.005) 0.940 <0.001 0.935 (0.914-0.956) 
Gender 0.128 (0.039) 1.136 0.001 1.069 (0.905-1.242) 
Age 0.014 (0.001) 1.015 <0.001 1.008 (1.002-1.015) 
Functioning (WSAS) -0.025 (0.003) 0.975 <0.001 0.975 (0.965-0.986) 
Therapy frequency -0.031 (0.002) 0.969 <0.001 0.992 (0.982-1.001) 
Therapy intensity -0.110 (0.050) 0.896 0.027 0.862 (0.724-1.036) 
Socioeconomic status 
(median IMD) 
-0.015 (0.013) 0.986 0.258 0.981 (0.934-1.031) 
Therapist level 
(between) 
Number of patients 0.000 (<0.001) 1.000 0.750 1.000 (0.999-1.002) 
* All independent variables were cross-adjusted 
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Supplementary Figure 1: Conceptual path diagram of unconditional nonlinear growth model. Squares represent observed 
scores (PHQ-9 or GAD-7) at first 20 appointments, ovals represent latent intercepts (I), slopes (S) and quadratic terms (Q). 
Dashed arrows show fixed parameters. 
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Supplementary Table 1: List of available variables routinely collected in IAPT 
and derived variables. Variables in bold were used as predictors, variables in 
italics were used to derive additional variables. 
Available variables routinely collected in IAPT Derived variables 
Therapy intensity Age (derived from Year and Month of birth) 
PHQ-9 IMD (derived from Postcode) 
GAD-7 
Therapy frequency (derived from Appointment 
dates) 
WSAS (at baseline) Number of patients (derived from Therapist ID) 
Gender 
Recovery (derived from PHQ-9, GAD-7, 
Appointment number, and End of care reason) 
Postcode 
(we had access to outward area portion of 
postcode) 
 
Therapist ID  
Appointment Date  
Appointment number  
Month of birth  
Year of birth  
End of care reason  
End of care date  
Ethnicity  
Referral date  
Site  
Service code  
Religion  
Sexuality  
Problem descriptor  
Service research  
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